The Price of Global Health: Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation / Edition 3

by Ed Schoonveld

Overview

The Price of Global Health is a unique book that describes the pharmaceutical pricing process and its business, economic and social challenges. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death?

The pharmaceutical industry is under unprecedented pressure due to a combination of declining R&D productivity, payer/provider demands for better value and public pressures to show pricing restraint. Rapidly increasing cost of healthcare, shifts from fee-for-service to value-based reimbursement, public pressure on drug pricing and an increasingly vocal medical community have empowered public and private payers worldwide to be more demanding on evidence of value for the prescription drugs that are brought to market. Pharmaceutical companies have often failed to deliver evidence of patient value, as development decision-making is overly focused on speed to FDA approval rather than speed to commercial success by effectively addressing the many “Access Journey” obstacles that typify today’s much changed pharmaceutical environment.

This 3rd edition is significantly expanded with ten new chapters and revised and updated throughout to reflect today’s environment. The contents are reorganized to directly address critical pricing and patient access issues. Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers, consumers, pharmaceutical company leaders and access and pricing professionals to gain a better understanding of this highly complex and emotionally charged field.

Product Details

ISBN-13:	9780367279400
Publisher:	Taylor & Francis
Publication date:	06/03/2020
Edition description:	3rd ed.
Pages:	626
Product dimensions:	6.88(w) x 9.69(h) x (d)

About the Author

Ed Schoonveld has 30+ years of experience in pharmaceutical pricing and access. He is currently Managing Partner of the Value and Access Practice with ZS Associates. He led global pricing functions for Wyeth, Lilly and BMS and consulting practices in Cambridge Pharma/IMS and Analytica International.

Table of Contents

Foreword Andrea Mantovani xi

About the author xiii

Acknowledgements xv

Preface xvii

Introduction 1

Part A The Challenges of Drug Pricing

Chapter 1 Why is drug pricing different? 7

Chapter 2 The age of value and affordability 35

Chapter 3 The Access Journey 45

Chapter 4 Fair pricing 55

Part B Traveling the Access Journey

Chapter 5 Payers 69

Chapter 6 Medical community 81

Chapter 7 Provider organizations 89

Chapter 8 Patients 95

Part C Pricing and Payer Management Techniques

Chapter 9 Fundamentals of pricing 101

Chapter 10 Reference-based pricing 117

Chapter 11 Health economics and outcomes research 125

Chapter 12 Attributes, benefits, value and price 141

Part D Structured Access and Pricing Approaches

Chapter 13 Pricing and drug development 157

Chapter 14 Payer segmentation 181

Chapter 15 The PODiUM framework 201

Chapter 16 BEST framework 213

Chapter 17 Drug development options and decisions 239

Chapter 18 Value story and messaging 249

Part E Developing an Integrated Global Strategy

Chapter 19 Developing a global pricing strategy 271

Chapter 20 Public policy 295

Chapter 21 Oncology and orphan drugs 309

Chapter 22 Gene and cell therapies 321

Chapter 23 Biosimilars 327

Chapter 24 Payer and pricing research 333

Part F Access and Pricing Strategy Implementation

Chapter 25 Organizing for access 359

Chapter 26 Access and price negotiations 371

Chapter 27 Value-based agreements 383

Chapter 28 Creating win-win partnerships 395

Part G Key Healthcare Systems

Chapter 29 United States 405

Chapter 30 Canada 437

Chapter 31 France 451

Chapter 32 Germany 463

Chapter 33 Italy 477

Chapter 34 Spain 489

Chapter 35 United Kingdom 497

Chapter 36 Japan 507

Chapter 37 Australia 523

Chapter 38 Brazil 529

Chapter 39 China 537

Chapter 40 India 543

Chapter 41 South Korea 553

List of figures 561

List of tables 565

List of abbreviations 567

References 573

Index 585

Editorial Reviews

"This book gives a great overview and offers several perspectives on drug pricing issues. It provides comprehensive new insights such as the need to take benefits assessments of pharmaceuticals into consideration during all steps of drug development and market access. The mix of theory, in the form of underlying arguments and analytical frameworks, along with practical and up-to-date real-world'solutions, makes this book an outstanding reference." - Thomas Mueller, Head of Directorate General 1 "Drugs, Medical Devices, Biotechnology" Ministry of Health, Germany

"Ed Schoonveld does an extraordinary job of making one of the most complex and vital topics in the industry intelligible to both new and experienced audiences. Best of all, he leverages case studies and straightforward frameworks to provide a pragmatic approach for mastering the theory of global pricing and access. I keep his book in easy reach for my own reference or to share with others." - Susanne Laningham, Commercial Growth Capability Lead, Amgen

"This book is fantastic! … People will love it. It’s very well suited for a broad audience from student to professionals to non experts and will hopefully be useful to demystify the subject a little. … THE pharma pricing book!" - Ulf Staginnus, Senior Vice President, Head Global Market Access & Pricing at Ipsen

"The Price of Global Health is the most informative and comprehensive book I have read on the topic of global pharmaceutical pricing and market access. Ed is able to distill complex topics into simplified and pragmatic frameworks, including insightful perspectives on market segmentation, communicating value, and pricing. The final section provides a useful reference, describing how key global healthcare systems are structured and their approach for assessing value. I have recommended this book for members of my team as part of their initial training." - David Kaplan, former Senior Advisor, Global Payer Market Research, Eli Lilly

"Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. I have used the book to teach pharmaceutical pricing since the book first arrived on the market. It fills a huge unmet need. The students find that Ed’s book transforms the complex global pricing environment and the factors that influence the pricing process into an understandable and manageable entity. The book takes a lot of data and transforms the information into key concepts. I can’t imagine teaching global pharmaceutical pricing without Ed’s book." - Richard Truex PhD, Adjunct Professor St. Joseph’s University, Philadelphia

"The Price of Global Health is a rare book in pharmaceutical market access strategy that develops an understandable strategic perspective. It is based on considerable real-world experience and has been updated as the dynamics of the global pharma market have evolved. We used it as an important part of our onboarding process for all junior market access staff. Highly recommended." - Keith Hendricks, former Vice President, Decision Support Group, Corporate Strategic Planning, AbbVie

"This book should be on the shelves of every pharmaceutical company executive—in whatever discipline—and will prove invaluable to anyone interested in providing and financing modern healthcare." - Joe Zammit-Lucia, President and CEO, Cambridge Pharma Consultancy

"The Price of Global Health is a compelling and holistic introduction into the art and science of pricing." - Andreas Altemark, VP, Head of Market Access Hematology and Ophthalmology, Bayer

From the Publisher